Eluminex Biosciences Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
65
- Latest Deal Type
-
Series B1
- Latest Deal Amount
-
$9.2M
- Investors
-
11
Eluminex Biosciences General Information
Description
Manufacturer of ophthalmic therapeutics designed to treat vision-threatening retinal and ocular diseases. The company develops protein- and antibody-based drugs targeting conditions such as wet age-related macular degeneration, diabetic macular edema, and retinal vascular disorders, enabling healthcare providers to address unmet needs in ophthalmology through innovative treatments.
Contact Information
Website
www.eluminexbio.comCorporate Office
- Unit 401, Building B7, Suzhou Biomedical Industrial Park
- Number 218 Xinghu Street
- Suzhou, Jiangsu 215123
- China
Corporate Office
- Unit 401, Building B7, Suzhou Biomedical Industrial Park
- Number 218 Xinghu Street
- Suzhou, Jiangsu 215123
- China
Eluminex Biosciences Timeline
Eluminex Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series B1) | 20-Aug-2023 | $9.2M | Completed | Generating Revenue | ||
| 2. Early Stage VC (Series B) | 14-Feb-2023 | Completed | Generating Revenue | |||
| 1. Early Stage VC (Series A) | 20-Nov-2020 | $50M | $50M | Completed | Generating Revenue |
Eluminex Biosciences Signals
Eluminex Biosciences Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Oriza FOFs | Fund of Funds | Minority | ||
| Suzhou Guofa Venture Capital | Venture Capital | Minority | ||
| Suzhou Trust | Limited Partner | Minority | ||
| 3E Bioventures (China) | Venture Capital | Minority | ||
| Beijing Jiurui Tiancheng Technology | Venture Capital | Minority |
Eluminex Biosciences Acquisitions (1)
Eluminex Biosciences’s most recent deal was a Merger/Acquisition with Retinagenix Holdings. The deal was made on 19-Jan-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Retinagenix Holdings | 19-Jan-2022 | Merger/Acquisition | Drug Discovery |
Eluminex Biosciences FAQs
-
When was Eluminex Biosciences founded?
Eluminex Biosciences was founded in 2020.
-
Where is Eluminex Biosciences headquartered?
Eluminex Biosciences is headquartered in Suzhou, China.
-
What is the size of Eluminex Biosciences?
Eluminex Biosciences has 65 total employees.
-
What industry is Eluminex Biosciences in?
Eluminex Biosciences’s primary industry is Drug Discovery.
-
Is Eluminex Biosciences a private or public company?
Eluminex Biosciences is a Private company.
-
What is Eluminex Biosciences’s current revenue?
The current revenue for Eluminex Biosciences is .
-
How much funding has Eluminex Biosciences raised over time?
Eluminex Biosciences has raised $100M.
-
Who are Eluminex Biosciences’s investors?
Oriza FOFs, Suzhou Guofa Venture Capital, Suzhou Trust, 3E Bioventures (China), and Beijing Jiurui Tiancheng Technology are 5 of 11 investors who have invested in Eluminex Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process